Myelodysplastic Syndromes
Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | December 30, 2024
HMAs, either as monotherapy or in combination with venetoclax, represent the standard of care for higher-risk MDS or AML.
Leah LawrenceMeeting News | December 27, 2024
According to a study, patients with MDS and CMML have dismal clinical outcomes after failure of HMA therapy.
Leah LawrenceMeeting News | December 27, 2024
Investigational combinations for MDS appeared to be well tolerated while triplets results in high-grade toxicity.
Esther OlivaMyelodysplastic Syndromes | December 27, 2024
An expert speak on site at ASH 2024 about the Health-related quality of life data from the phase 3 COMMANDS trial.
Leah LawrenceAcute Myeloid Leukemia | December 26, 2024
Phase 2 study results outline benefit of adding venetoclax to intensive chemo in MDS and AML patients.
Blood Cancers Today Staff WritersMeeting News | December 24, 2024
Moving forward, prospective studies must validate these findings and refine risk stratification tools like the IPSS-R in MDS.
Advertisement
Blood Cancers Today Staff WritersMeeting News | December 24, 2024
Some patients with ZRSR2-mutated CCUS had concurrent blood cancers or disorders, and others had protective co-mutation.
Jamile Shammo, MDMyelodysplastic Syndromes | December 23, 2024
A discussion on the post hoc analysis on quality of life from the COMMANDS trial.
Thomas LeBlanc, MD, MAMyelodysplastic Syndromes | December 23, 2024
Discussing the COMMANDS trial and sequencing luspatercept in patients with myelodysplastic syndromes.
Thomas LeBlanc, MD, MAMyelodysplastic Syndromes | December 23, 2024
How to address ESA failure or ineligibility in patients with MDS...
Thomas LeBlanc, MD, MAMyelodysplastic Syndromes | December 23, 2024
Results from a real-world analysis of post-ESA treatment outcomes in patients with lower-risk myelodysplastic syndrome.
Patrick DalyMeeting News | December 20, 2024
Early signs of clinical activity have been shown in a phase I/II study of tagraxofusp/decitabine in MDS and CMML.
Patrick DalyMeeting News | December 20, 2024
Mature data of three immunotherapy-based hypomethylating agent combinations were presented at ASH.
Patrick DalyAcute Myeloid Leukemia | December 20, 2024
High complete response rates and low early mortality rates facilitate the majority of patients to allogeneic SCT.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
An ongoing phase 1 study is evaluating the safety and efficacy of danvatirsen through two substudies.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
New WHO and ICC 022 guidelines propose lowering the threshold for diagnosis of CMML.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
High-risk MDS is associated with poor outcomes, making the assessment of treatment response critical.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
A myelofibrosis cohort showed that tapering to achieve molecular remission helped promote OS after transplant.
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
The design of a phase 3 trial of elritercept for transfusion-dependent anemia in lower-risk MDS was presented at ASH 2024.
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
Increasing evidence suggests a connection between acquired somatic mutations and inflammatory processes in myeloid neoplasms.
Advertisement
Advertisement
Editorial Board